RefleXion Medical, Inc., a biotargeting oncology company developing the first and only biology-guided radiotherapy (BgRT) machine* for targeted cancer treatment has received a $60M senior secured term loan from Oxford Finance LLC. The company plans to use the loan to support the completion of the FDA clearance process for its biology-guided BgRT system and its subsequent commercial launch. Building from Positron
Emission Tomography Positron emission tomography (PET) is an established
Read More
Cancer Detection
Guardant Health to Acquire Cancer Diagnostic Company Bellwether Bio
Precision oncology company Guardant Health, Inc., announced that it
has entered into a definitive agreement to acquire
Seattle-based Bellwether Bio, an
oncology startup developing next generation cancer diagnostics using cell-free
DNA. The acquisition is expected to close in April 2019. Financial terms of the
acquisition were not disclosed. Bellwether Bio Background Spun out of the University of Washington in 2016, Bellwether
Bio (formerly known as Haverhill Genetics) is developing
Read More
Proscia Raises $8M for AI-Enhanced Digital Pathology for Cancer Diagnosis
Proscia, a Philadelphia-based digital pathology platform has raised $8.3 million in Series A funding led by Boston-based Flybridge Capital Partners with participation from Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, and RobinHood Ventures.The startup plans to utilize the Series A funding to fuel the development and commercialization of new, clinical AI-enabled workflows targeting high-volume, high-impact cancers, the first of which will be available later this year. In
Read More
Elsevier Acquires Clinical Decision Support Solution Via Oncology
Elsevier, the information analytics business specializing in science and health, and part of RELX Group, today announced that it has acquired Via Oncology, a Pittsburgh, Pennsylvania-based company that provides clinical decision support and best practices in cancer care management. A former subsidiary of UPMC, one of the nation's leading integrated healthcare delivery and financing systems, Via Oncology helps cancer centers demonstrate the value of their care to patients, referring physicians
Read More
GRAIL Lands $900M for Early Cancer Detection
GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced it has raised $900 million in Series B funding led by ARCH Venture Partners with participation from Johnson & Johnson Innovation, Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck (known as MSD outside the United States and Canada), Tencent Holdings Limited and Varian Medical Systems, Inc. GRAIL intends to close the remainder of the Series B investment prior to the
Read More
Early Detection: The New Cancer Paradigm
Editor's Note: Amit Kumar, Ph.D, is an expert in cancer diagnostics with over 20 years of experience in cancer research. He is the Vice Chairman of ITUS Corporation and Executive Chairman of Anixa Diagnostics Corporation, which is developing a blood test (Cchek ™), for the early detection of tumor-based cancers. This article first appeared in The Journal of Antibody Drug Conjugates and has been republished with permission.
A seemingly healthy patient walks into the doctor’s office for a
Read More
Guardant Health Nabs $100M for Biopsy-Free Cancer Genomic Testing
Guardant Health, a Redwood City, CA-based company revolutionizing cancer detection through biopsy-free tumor sequencing has raised $100M in Series D funding led by healthcare-investment firm OrbiMed. Existing Guardant Health investors Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, Heritage Group, and others also participated in the funding round.
Founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell
Read More
